NGS Whole Exome + PD-L1 (22C3) Package: Lab Accreditation and Assay Validation

Overview

The combined package of whole exome sequencing and PD-L1 immunohistochemistry with the 22C3 clone is a molecular profiling service whose reliability rests on laboratory accreditation and rigorous assay validation. For B2B and institutional buyers, the compliance framework matters as much as the report content, because the output informs high-stakes treatment decisions.

How It Works

Whole exome sequencing reads the protein-coding regions of the tumor genome to surface somatic mutations, copy-number shifts and variants that inform targeted or immunotherapeutic options. In parallel, PD-L1 22C3 immunohistochemistry stains formalin-fixed tissue and scores the proportion of tumor cells with membrane expression, a biomarker linked to checkpoint-inhibitor likelihood. The two modalities are complementary: sequencing finds actionable alterations while the 22C3 assay reports the immune microenvironment signal, and both feed a single integrated interpretation. Bioinformatic pipelines then annotate variants by clinical relevance and guideline status.

Indications

The package supports oncologists selecting among targeted agents, immunotherapy or trial options for advanced solid tumors. It is a decision-support tool rather than a therapy, used when a comprehensive molecular picture will guide treatment choice or eligibility. It is particularly relevant when standard tissue typing has been exhausted and a broader search is warranted.

Sample Collection & Handling

Tissue is submitted as formalin-fixed paraffin-embedded blocks or curls; plasma or blood may support orthogonal analysis depending on the lab workflow. Specimens are accessioned, quality-checked for tumor content, and tracked through barcode identity to prevent mix-ups before sequencing and staining begin. Failed quality checks trigger a recollection request rather than a guessed report.

Storage & Sourcing

Reagents and reference standards are stored under controlled conditions with documented expiry, and the report carries the assay version and validation statement. Buyers should confirm the laboratory holds relevant accreditation, that the 22C3 assay is validated against the intended companion-diagnostic claim, and that turnaround and reporting format meet their workflow. A clear chain-of-custody record supports audit readiness.

FAQ

Q: Why pair whole exome sequencing with PD-L1 22C3 rather than either alone? A: Sequencing reveals targetable alterations while 22C3 reports immune fitness, so together they cover both targeted and immunotherapy directions in one workflow.

Q: What accreditation should the lab demonstrate? A: Buyers should look for recognized laboratory accreditation and documented validation for each assay, including the 22C3 clone against its intended clinical claim.

Q: How are sample identity and quality controlled? A: Barcode tracking and pre-sequencing tumor-content checks reduce mix-up and failed runs, and only passing samples proceed to reporting.